Nothing Special   »   [go: up one dir, main page]

BR112015018047A8 - método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas - Google Patents

método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas Download PDF

Info

Publication number
BR112015018047A8
BR112015018047A8 BR112015018047A BR112015018047A BR112015018047A8 BR 112015018047 A8 BR112015018047 A8 BR 112015018047A8 BR 112015018047 A BR112015018047 A BR 112015018047A BR 112015018047 A BR112015018047 A BR 112015018047A BR 112015018047 A8 BR112015018047 A8 BR 112015018047A8
Authority
BR
Brazil
Prior art keywords
heparinoid
buffer
compositions
acute
acting anesthetic
Prior art date
Application number
BR112015018047A
Other languages
English (en)
Other versions
BR112015018047A2 (pt
Inventor
Lowell Parsons C
Original Assignee
Urigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urigen Pharmaceuticals Inc filed Critical Urigen Pharmaceuticals Inc
Publication of BR112015018047A2 publication Critical patent/BR112015018047A2/pt
Publication of BR112015018047A8 publication Critical patent/BR112015018047A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão” a presente invenção refere-se a métodos aprimorados para preparar composições que incluem um heparinoide, um anestésico de ação aguda e um tampão. esses métodos resultam em composições em que o heparinoide e o anestésico de ação aguda são pelo menos 90% estáveis por um ano. as composições preparadas por esses métodos e que têm tais propriedades de estabilidade aprimoradas são também descritos, assim como métodos para uso dessas composições para tratar, melhorar ou impedir distúrbios do trato urinário inferior, tal como cistite intersticial. 1/1
BR112015018047A 2013-01-28 2014-01-28 método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas BR112015018047A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757592P 2013-01-28 2013-01-28
PCT/US2014/013352 WO2014171986A1 (en) 2013-01-28 2014-01-28 Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer

Publications (2)

Publication Number Publication Date
BR112015018047A2 BR112015018047A2 (pt) 2017-07-18
BR112015018047A8 true BR112015018047A8 (pt) 2019-11-05

Family

ID=51731742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018047A BR112015018047A8 (pt) 2013-01-28 2014-01-28 método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas

Country Status (13)

Country Link
US (1) US20150359816A1 (pt)
EP (1) EP2948154A4 (pt)
JP (2) JP2016517390A (pt)
KR (1) KR20160008496A (pt)
CN (1) CN105263503A (pt)
AU (2) AU2014254472A1 (pt)
BR (1) BR112015018047A8 (pt)
CA (1) CA2899636C (pt)
IL (1) IL240194B (pt)
MX (1) MX2015009696A (pt)
SG (1) SG11201505853RA (pt)
WO (1) WO2014171986A1 (pt)
ZA (1) ZA201505814B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117847B2 (en) * 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
CA3061891A1 (en) * 2017-04-12 2018-10-18 Urigen Pharmaceuticals, Inc. Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability
EP3400951B1 (de) * 2017-05-12 2019-12-11 Farco-Pharma GmbH Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis
EP3415163B1 (de) * 2017-06-13 2023-02-22 Farco-Pharma GmbH Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung
JP7083968B2 (ja) * 2019-04-26 2022-06-13 ティーシーエム バイオテック インターナショナル コーポレーション 再発性尿路感染症の予防のための医薬組成物
TW202105790A (zh) * 2019-05-17 2021-02-01 日商半導體能源研究所股份有限公司 發光元件、發光裝置、電子機器及照明裝置
JP2022550658A (ja) * 2019-07-18 2022-12-05 シー ローウェル パーソンズ 膀胱痛症状の緩和を促進するための、膀胱内ヘパリンおよびアルカリ化リドカインによる治療前の、膀胱壁のアルカリ化
CN115814099B (zh) * 2022-12-19 2024-04-26 成都蓉生药业有限责任公司 一种人凝血因子ix的干热处理稳定剂及其制剂与制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603695A (en) * 1995-06-07 1997-02-18 Erickson; Kim Device for alkalizing local anesthetic injection medication
EP2813231A1 (en) * 2004-01-28 2014-12-17 The Regents of The University of California Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
DK2839830T3 (da) * 2005-01-14 2019-08-19 Urigen Inc Kits og sammensætninger til behandling af lidelser i de nedre urinveje
WO2007073397A1 (en) * 2005-12-19 2007-06-28 Urigen, Inc. Kits and improved compositions for treating lower urinary tract discorders
US8357795B2 (en) * 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US9107885B2 (en) * 2009-08-13 2015-08-18 Lubris Llc PRG4 treatment for interstitial cystitis
US20140194380A1 (en) * 2011-01-06 2014-07-10 Lowell C. Parsons Method of manufacturing composition comprising local anesthetic, heparinoid, and buffer
US9486747B2 (en) * 2014-08-12 2016-11-08 The Curators Of The University Of Missouri Nanocomposite membranes with advanced antifouling properties under visible light irradiation

Also Published As

Publication number Publication date
CA2899636C (en) 2021-05-25
BR112015018047A2 (pt) 2017-07-18
MX2015009696A (es) 2016-03-31
IL240194A0 (en) 2015-09-24
JP2016517390A (ja) 2016-06-16
CA2899636A1 (en) 2014-10-23
CN105263503A (zh) 2016-01-20
WO2014171986A1 (en) 2014-10-23
SG11201505853RA (en) 2015-08-28
EP2948154A1 (en) 2015-12-02
AU2014254472A1 (en) 2015-08-20
EP2948154A4 (en) 2016-09-14
JP2019006783A (ja) 2019-01-17
US20150359816A1 (en) 2015-12-17
ZA201505814B (en) 2016-11-30
IL240194B (en) 2021-12-01
AU2018247284A1 (en) 2018-11-01
KR20160008496A (ko) 2016-01-22

Similar Documents

Publication Publication Date Title
BR112015018047A8 (pt) método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas
PH12018501226A1 (en) Methods for treating huntingtons disease
AU2018236800B2 (en) DNA-PK inhibitors
MX2018005829A (es) Composiciones para tratar el cabello.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2017012512A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MD20150062A2 (ro) Compuşi antivirali
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
BR112017002963A2 (pt) derivados citotóxicos de benzodiazepina
MX2020002544A (es) Sales de glicopirrolato.
WO2016164896A3 (en) Modulation of smn expression
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
BR112015029462A2 (pt) Inibidores de quinase
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements